Incyte Corporation Announces Late‑Breaking Data on Hidradenitis Suppurativa at the 2026 American Academy of Dermatology Annual Meeting

Incyte Corporation (Nasdaq: INCY) announced on 20 March 2026 that key results from its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled for 27–31 March in Denver.

The company highlighted that the presentation will include late‑breaking 54‑week data from the Phase‑3 STOP‑HS program evaluating povorcitinib in patients with hidradenitis suppurativa (HS). The data are expected to extend the 52‑week findings previously reported and provide additional insight into efficacy and safety over a longer treatment period.

In addition to the povorcitinib results, Incyte will feature multiple ePosters on its ruxolitinib cream (Opzelura®) and povorcitinib in the areas of atopic dermatitis, hidradenitis suppurativa, and vitiligo. The abstracts will be showcased across the conference’s poster sessions and oral presentations.

“At AAD 2026, we are presenting late‑breaking 54‑week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer‑term evidence on the therapeutic profile of povorcitinib and will inform clinicians and stakeholders about its potential role in HS treatment.”

Market Context

  • Current share price (18 March 2026): USD 92.95
  • 52‑week high: USD 112.29 (6 January 2026)
  • 52‑week low: USD 53.56 (8 April 2025)
  • Market capitalization: USD 18.32 billion
  • Price‑earnings ratio: 14.43

The company’s performance over the past five years shows a modest gain. An investment of USD 1,000 made at the close of 2011 (USD 79.37) would be worth approximately USD 1,162.15 today (USD 92.24), reflecting a 16.22 % return, before accounting for splits or dividends.

Strategic Implications

The upcoming presentation at AAD positions Incyte to showcase the clinical development of its small‑molecule pipeline, particularly povorcitinib, which aligns with the company’s focus on oncology and inflammatory diseases. The 54‑week data will provide a more comprehensive safety and efficacy profile, potentially influencing regulatory discussions and market adoption.

Company Overview

Incyte Corporation is a biopharmaceutical company headquartered in Wilmington, Delaware. The company specializes in discovering, developing, and commercializing proprietary small‑molecule drugs, primarily for oncology indications. It trades on the Nasdaq exchange under the ticker INCY.